2.80Open2.60Pre Close30 Volume31 Open Interest10.00Strike Price8.50KTurnover131.11%IV2.46%PremiumSep 20, 2024Expiry Date2.67Intrinsic Value100Multiplier19DDays to Expiry0.18Extrinsic Value100Contract SizeAmericanOptions Type-0.8111Delta0.1251Gamma2.57Leverage Ratio-0.0145Theta-0.0036Rho-2.09Eff Leverage0.0045Vega
Biomea Fusion Stock Discussion
The pause on clinical trials seems to be a result of the explosion of industry regulations in recent years. From 2022 through 2024, the FDA has implemented "additional steps" to clinical trials, including bringing in outside agencies to help with oversight.
Red tape and bureaucracy, not BEMA, caused this pause. All the research I've done shows the pause was premature and overly cautious.
No comment yet